Welcome to our dedicated page for Glucose Health news (Ticker: GLUC), a resource for investors and traders seeking the latest updates and insights on Glucose Health stock.
Glucose Health, Inc. (OTC: GLUC) is a consumer-health company focused on soluble-fiber nutrition products for metabolic support, including its GlucoDown and Fiber Up brands. The GLUC news feed on Stock Titan aggregates company press releases and market updates so readers can follow how Glucose Health, Inc. is executing its strategy in the fiber-based nutrition and diabetic nutrition categories.
News about Glucose Health, Inc. often covers capital structure changes, such as preferred stock conversions, note settlements, and board-level decisions intended to simplify the balance sheet and support future financing. Articles also highlight management and board appointments, bringing in executives and directors with experience in financial services, securities, and consumer marketing to guide the company’s growth plans.
Operational updates in GLUC news include information on brand performance and distribution, such as national in‑store placement of GlucoDown in the diabetic‑care sections of CVS and Walgreens pharmacies, high consumer ratings and review counts on Amazon, and the launch or expansion of Fiber Up within the soluble fiber supplement market. The company also issues news about product development, including its patent‑pending soluble fiber formulations, clean‑label ingredient profile, and plans for additional fiber-based formats like sodas, waters, and nutrition bars.
Investors and observers can use the GLUC news page to review announcements on strategic revenue growth plans, media campaigns on major financial news networks, and the company’s alignment with public‑health priorities related to dietary fiber intake. Bookmark this page to access a centralized stream of Glucose Health, Inc. news, from financing and governance developments to product and distribution milestones in the soluble-fiber nutrition space.
Glucose Health, Inc. (OTC Pink: GLUC) announced significant changes to its Board of Directors amid concerns regarding potential violations of securities laws connected to Celsius Holdings. The company's CEO and a board member from Celsius resigned following the revelation of an SEC investigation into Celsius. Consequently, 1.8 million shares underlying the resigned directors' warrants were canceled, reducing GLUC's fully diluted share count from 22.1 million to 20.3 million. This restructuring positions Glucose Health to refocus on its unique market of functional, diabetic-friendly beverages.
Glucose Health, Inc. (OTC Pink: GLUC) announced the resignations of board members Hal Kravitz and John Fieldly, signaling potential changes in governance. The company focuses on functional beverages, specifically for over 100 million pre-diabetics and Type-2 diabetics in the U.S. In 2022, it plans to launch a new ready-to-drink beverage targeting consumers aged 45 and above. Despite this expansion, the departure of board members may raise concerns regarding future strategic direction.
Glucose Health, Inc. (OTC: GLUC) reported significant growth in its Fiscal 2021 Annual Report. Revenues surged by 98% to $953,681, with gross profits up 136% to $410,042. The company achieved a debt-free status, with total liabilities reduced to $9,554 from $380,652 in the previous year. New product launches, including the highly successful GLUCODOWN® Cherry, contributed to this growth. For Fiscal 2022, Glucose Health plans to strengthen distribution partnerships and launch a new ready-to-drink beverage aimed at the 45+ demographic.
Glucose Health, Inc. (OTC Pink: GLUC) announced the filing of a patent application with the USPTO on December 23, 2021, for its innovative composition aimed at enhancing metabolic health. The formulation, comprising resistant dextrin, corosolic acid, and chromium picolinate, targets post-prandial glycemic and lipid spikes, offering potential benefits in lowering plasma glucose and lipids. This patented composition underpins the Company's GLUCODOWN® product line, which caters to over 100 million pre-diabetic and Type-2 diabetic individuals in the U.S.
Glucose Health, Inc. (OTC Pink: GLUC) reported significant financial growth in its Fiscal 2021 Third Quarter, ending September 30, 2021. The company achieved a 110% increase in revenue for the nine months, totaling $759,498 compared to $361,256 in the previous year. For Q3, revenue rose 86% to $234,930. Gross profit for the nine months jumped 69% to $279,748, with Q3 gross profit rising 25% to $85,714. GLUCODOWN® continues to gain popularity, boasting high ratings on Amazon.
Glucose Health, Inc. (OTC Pink: GLUC) has launched new flavors of its diabetic-friendly drink mixes, GLUCODOWN®, on Amazon after 16 months of development. The flavors include Delicious Cherry, Peach Mango, Watermelon, and Strawberry Banana. GLUCODOWN® stands out as North America's first non-dairy beverage enriched with soluble fiber to support healthy blood sugar levels, featuring no sugar or caffeine. The drinks are also marketed toward those on KETO diets. A 5% discount is available for purchases until midnight this Friday.
Glucose Health, Inc. (GLUC) reported significant financial advancements for H1 2021, declaring itself debt-free with zero liabilities on its balance sheet. The company effectively managed its debt reduction strategy, resulting in a 1/3 reduction of share count, preventing potential dilution from convertible debts. As of June 30, 2021, it has 22,128,632 fully diluted common shares, with 13,848,630 issued. Glucose Health focuses on producing diabetic-friendly beverages, positioning itself as a leader in this emerging market.
Glucose Health, Inc. (OTC Pink: GLUC) reported strong fiscal performance for the second quarter of 2021 and year-to-date results. Fiscal 2021 year-to-date revenue reached $524,568, a 123% increase from $234,752 in 2020. The second quarter revenue was $287,103, up 89% from $151,139 the previous year. Gross profit also surged, with year-to-date gross profit at $217,794 (up 125%) and Q2 at $102,923 (up 47%). GLUCODOWN® sales hit a record $74,944 in April 2021, showcasing strong market demand.